This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The six strategies were as follows:
CBZ first-line monotherapy followed by either VPA or LTG if CBZ failed because of either a lack of seizure control or adverse effects; VPA first-line monotherapy followed by either CBZ or LTG if VPA failed because of either a lack of seizure control or adverse effects; and LTG first-line monotherapy followed by either CBZ or VPA if LTG failed because of either a lack of seizure control or adverse effects.
Location/setting
Netherlands/secondary care.
Methods

Analytical approach:
A decision tree analysis populated with published clinical evidence was developed in order to simulate the outcomes of the six alternative options. The time horizon was 1 year of treatment. The authors stated that a societal perspective was adopted.
Effectiveness data:
A review of the literature was undertaken in order to identify relevant sources of clinical estimates. The inclusion criteria were reported in detail. Most of the clinical data were derived from randomised clinical trials (RCTs), but no direct comparison among the drugs under study was available. Some observational studies were also used. It appears that the authors have used their judgement to select the most appropriate estimate from the available evidence found in the literature. The key clinical input was treatment effectiveness, i.e. the success rate (freedom from seizure).
